The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Orbicin     (2R,3R,4S,5S,6R)-4-amino-2- [(1S,2S,3R,4S...

Synonyms: Debecacin, Icacine, Kappati, Panamicin, dibekacin, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dideoxykanamycin B


High impact information on Dideoxykanamycin B


Chemical compound and disease context of Dideoxykanamycin B


Biological context of Dideoxykanamycin B

  • The pharmacokinetics of dibekacin, a new aminoglycoside antibiotic, was studied in volunteers given the same dose (100 mg) intramuscularly on two separate occasions and intravenously at two different rates of infusion [14].
  • Changes were also observed in the distribution kinetics of dibekacin in the rabbit on varying the infusion conditions, suggesting alterations in the access and permanence of the antibiotic in tissues [15].
  • Dibekacin-treated animals showed a significant (P less than 0.05) increase in the thresholds of the Preyer pinna reflex and the VIIIth nerve compound action potential in response to sound click stimulation [16].
  • The LD50 values of dibekacin to mice were determined following three different methods of administration, namely, intravenous constant infusion, intravenous bolus injection, and intramuscular injection [17].
  • Dibekacin was noted to bind with brush-border membrane vesicles having a single class of many binding sites [18].

Anatomical context of Dideoxykanamycin B

  • Among presently available aminoglycosides, dibekacin has the least toxic effect on the functions of the cochlea and the vestibule [19].
  • The antibiotic binding to the 70S ribosome and 1.15 M LiCl core reconstituted with S9 and L6 was considerably inhibited by unlabelled dibekacin or kanamycin, and partially inhibited by gentamicin or neomycin, but was not significantly affected by streptomycin or viomycin [20].
  • Seventy-four semen samples were stored at 15 degrees C by means of dialysis in the presence of dibekacin (100 micrograms/ml) [21].
  • The degree of changes of the cell wall ultrastructure was almost proportional to the length of incubation with dibekacin [22].
  • Consequently, the amounts of dibekacin reaching the inner ear are decreased, and ototoxicity is reduced [23].

Associations of Dideoxykanamycin B with other chemical compounds


Gene context of Dideoxykanamycin B


Analytical, diagnostic and therapeutic context of Dideoxykanamycin B


  1. Comparative in vitro activities of SCE-129, sulbenicillin, gentamicin, and dibekacin against Pseudomonas. Tsuchiya, K., Kondo, M. Antimicrob. Agents Chemother. (1978) [Pubmed]
  2. In vitro comparison of third-generation cephalosporins, piperacillin, dibekacin, and other aminoglycosides against aerobic bacteria. Pulliam, L., Hadley, W.K., Mills, J. Antimicrob. Agents Chemother. (1981) [Pubmed]
  3. Relation between aminoglycoside 2"-O-nucleotidyltransferase activity and aminoglycoside resistance. Bongaerts, G.P., Molendijk, L. Antimicrob. Agents Chemother. (1984) [Pubmed]
  4. Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus. Tanigawara, Y., Sato, R., Morita, K., Kaku, M., Aikawa, N., Shimizu, K. Antimicrob. Agents Chemother. (2006) [Pubmed]
  5. Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use. Noone, P. Drugs (1984) [Pubmed]
  6. Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United States. Shimizu, K., Kumada, T., Hsieh, W.C., Chung, H.Y., Chong, Y., Hare, R.S., Miller, G.H., Sabatelli, F.J., Howard, J. Antimicrob. Agents Chemother. (1985) [Pubmed]
  7. Rapid method for determination of kanamycin and dibekacin in serum by use of high-pressure liquid chromatography. Kubo, H., Kobayashi, Y., Nishikawa, T. Antimicrob. Agents Chemother. (1985) [Pubmed]
  8. Intra- and extracellular susceptibility of Mycobacterium avium-intracellulare complex to aminoglycoside antibiotics. Nozawa, R.T., Kato, H., Yokota, T. Antimicrob. Agents Chemother. (1984) [Pubmed]
  9. Evaluation of urinary elimination of N-acetyl-beta-glucosaminidase in healthy volunteers treated with dibekacin or gentamicin. Camí, J., Segura, J., Baños, J.E., Garcia, I., Drobnic, L. Antimicrob. Agents Chemother. (1982) [Pubmed]
  10. Synergistic effects of a macrolide and a cell wall-affecting antibiotic on Pseudomonas aeruginosa in vitro and in vivo. 2. Combined effects of a macrolide with a fosfomycin and an aminoglycoside antibiotic. Kasai, T., Homma, J.Y. J. Antibiot. (1982) [Pubmed]
  11. In vivo and in vitro cross-resistance of kanamycin-resistant mutants of E. coli to other aminoglycoside antibiotics. Choi, E.C., Nishimura, T., Tanaka, Y., Tanaka, N. J. Antibiot. (1980) [Pubmed]
  12. Electron microscopy of Pseudomonas aeruginosa treated with sulbenicillin and dibekacin. Aonuma, S., Ariji, F., Oizumi, K., Konno, K. Tohoku J. Exp. Med. (1987) [Pubmed]
  13. Neutrophil disorders in a child with necrotizing external otitis. Ichimura, K., Hoshino, T., Yano, J., Nozue, M. The Journal of otolaryngology. (1983) [Pubmed]
  14. Pharmacokinetic studies with dibekacin, a new aminoglycoside, after intravenous and intramuscular administration to human volunteers. Goto, M., Sugiyama, M., Ishizaki, T. Antimicrob. Agents Chemother. (1980) [Pubmed]
  15. Effect of infusion time on the pharmacokinetics of dibekacin in rabbits. Navarro, A.S., Lanao, J.M., Dominguez-Gil, A. J. Antibiot. (1984) [Pubmed]
  16. Comparative ototoxicity of dibekacin and netilmicin in guinea pigs. Parravicini, L., Forlani, A., Marzanatti, M., Arpini, A. Acta pharmacologica et toxicologica. (1983) [Pubmed]
  17. Acute toxicity and pharmacokinetics of dibekacin mice. Komiya, I., Murata, S., Umemura, K., Tomono, N., Kikai, S., Fujita, M. J. Pharmacobio-dyn. (1981) [Pubmed]
  18. Inhibition of alkaline phosphatase activity and D-glucose uptake in rat renal brush-border membrane vesicles by aminoglycosides. Takahashi, M., Aramaki, Y., Inaba, A., Tsuchiya, S. Biochim. Biophys. Acta (1987) [Pubmed]
  19. Renal histological and biochemical changes induced in the rat by dibekacin. Viotte, G., Olier, B., Morin, J.P., Fillastre, J.P. J. Pharmacol. Exp. Ther. (1983) [Pubmed]
  20. Ribosomal proteins S9 and L6 participate in the binding of [3H]dibekacin to E. coli ribosomes. Akiyama, T., Tanaka, N. J. Antibiot. (1981) [Pubmed]
  21. Effects of various antibiotics on the control of bacteria in boar semen. Sone, M., Ohmura, K., Bamba, K. Vet. Rec. (1982) [Pubmed]
  22. Electron microscopic study of the cell surface of dibekacin-treated Pseudomonas aeruginosa. Aonuma, S., Ariji, F., Oizumi, K., Konno, K. Tohoku J. Exp. Med. (1986) [Pubmed]
  23. Protective effect of fosfomycin against aminoglycoside ototoxicity. Ohtani, I., Ohtsuki, K., Aikawa, T., Sato, Y., Anzai, T., Ouchi, J., Saito, T. ORL J. Otorhinolaryngol. Relat. Spec. (1985) [Pubmed]
  24. In vitro comparison of dibekacin and gentamicin activities. Hill, C.D., Counts, G.W., Turck, M. Antimicrob. Agents Chemother. (1981) [Pubmed]
  25. Dibekacin assay in serum by automated fluorescence polarization immunoassay (Abbott Tdx): Comparison with high-performance liquid chromatography, substrate-labelled fluorescent immunoassay and radioimmunoassay. Rollman, B., Van Der Auwera, P., Tulkens, P.M. Journal of pharmaceutical and biomedical analysis. (1986) [Pubmed]
  26. Disposition kinetics of dibekacin in patients with renal failure and in patients undergoing hemodialysis. Arancibia, A., Baillarie, D., Bravo, M., Chávez, J. International journal of clinical pharmacology and therapeutics. (1995) [Pubmed]
  27. Pharmacokinetics of dibekacin in children with cystic fibrosis. Courcol, R.J., Loeuille, G.A., Delnatte, J., Martin, G.R. International journal of clinical pharmacology research. (1985) [Pubmed]
  28. Habekacin: nephrotoxicity, pharmacokinetics and prophylactic efficacy in rats. Stewens, J., Marre, R., Engelbart, K., Schulz, E., Sack, K. Arzneimittel-Forschung. (1985) [Pubmed]
  29. Substrate-labeled fluorescent immunoassay for measuring dibekacin concentrations in serum and plasma. Place, J.D., Thompson, S.G. Antimicrob. Agents Chemother. (1983) [Pubmed]
  30. Quantitative determination of dibekacin using radioimmunoassay, substrate-labelled fluorescent immunoassay and rate nephelometric inhibition immunoassay for tobramycin. Duriez, D., Dewilde, A., Marzin, D., Wattré, P. Ann. Inst. Pasteur Microbiol. (1985) [Pubmed]
WikiGenes - Universities